=== PAGE 5 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Kimberly Skopitz
Kowa Pharmaceuticals America, Inc.
NDA 022363 MA 609

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Livalo comply with each
applicable requirement of the FD&C Act and FDA implementing regulations.

                                                                                    Sincerely,

                                                                                    {See appended electronic signature page}

                                                                                    Ankur Kalola, PharmD, RAC
                                                                                    Regulatory Review Officer
                                                                                    Division of Advertising & Promotion Review 2
                                                                                    Office of Prescription Drug Promotion

                                                                                    {See appended electronic signature page}

                                                                                    Melinda McLawhorn, PharmD, MPH BCPS,
                                                                                    RAC
                                                                                    Team Leader
                                                                                    Division of Advertising & Promotion Review 2
                                                                                    Office of Prescription Drug Promotion
Page 5
Reference ID: 4496702
